From: Evaluation of QoL in neurofibromatosis patients: a systematic review and meta-analysis study
Researchers | Selection | Comparability | Exposure | ||||||
---|---|---|---|---|---|---|---|---|---|
1 | 2 | 3 | 4 | A | B | 1 | 2 | 3 | |
Page. PZ [19] | * | * | * | * | Â | Â | Â | * | * |
Kodra. Y [20] | * | * | Â | Â | Â | Â | Â | * | * |
Merker. VL [21] | * | * | * | * | * | Â | Â | * | * |
Vardarinos. A [22] | * | * | * | * | Â | Â | * | * | Â |
Ostenbrink. R [23] | * | * | * | * | * | Â | Â | * | * |
Wolkenstein. P [24] | * | Â | * | Â | * | Â | Â | * | * |
Hornigold. RE [25] | * | * | * | * | * | * | Â | * | * |
Krab. LC [26] | Â | * | * | Â | Â | Â | Â | * | * |
Hornigold. RE [27] | * | * | Â | Â | * | Â | * | * | Â |
Merker. VL [28] | Â | * | Â | * | Â | Â | Â | * | * |